Compare QCLS & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCLS | NEPH |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 31.0M |
| IPO Year | N/A | 2004 |
| Metric | QCLS | NEPH |
|---|---|---|
| Price | $3.82 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 342.8K | 21.0K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $27.87 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $2.50 | $1.88 |
| 52 Week High | $8.17 | $6.42 |
| Indicator | QCLS | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 50.21 |
| Support Level | $3.38 | $2.77 |
| Resistance Level | $3.86 | $3.18 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 41.91 | 60.44 |
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.